<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03896633</url>
  </required_header>
  <id_info>
    <org_study_id>883</org_study_id>
    <nct_id>NCT03896633</nct_id>
  </id_info>
  <brief_title>Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt</brief_title>
  <official_title>A BIOEQUIVALENCE STUDY OF THE GENERIC BRINZOLAMIDE 1% OPHTHALMIC SUSPENSION COMPARED TO REFERENCE LISTED DRUG AZOPTÂ® (BRINZOLAMIDE) OPHTHALMIC SUSPENSION 1% IN SUBJECTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this prospective study is to demonstrate the therapeutic equivalence of&#xD;
      topical brinzolamide compared with AzoptTM&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this prospective study is to demonstrate the therapeutic equivalence of&#xD;
      topical brinzolamide dosed three times daily compared with AzoptTM (brinzolamide ophthalmic&#xD;
      suspension 1%) dosed three times daily in IOP reduction in patients with POAG or OH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2018</start_date>
  <completion_date type="Actual">November 17, 2018</completion_date>
  <primary_completion_date type="Actual">November 17, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Change in Intraocular Pressure (IOP)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in intraocular pressure (IOP) from baseline (Eligibility Visit 2) and after treatment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">637</enrollment>
  <condition>Glaucoma</condition>
  <condition>Open Angle or Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Azopt 1% ophthalmic suspension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ophthalmic suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brinzolamide 1% ophthalmic suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ophthalmic suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brinzolamide 1% ophthalmic suspension</intervention_name>
    <description>brinzolamide 1% ophthalmic suspension</description>
    <arm_group_label>Brinzolamide 1% ophthalmic suspension</arm_group_label>
    <other_name>brinzolamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azopt 1%</intervention_name>
    <description>Azopt 1%, RLD</description>
    <arm_group_label>Azopt 1% ophthalmic suspension</arm_group_label>
    <other_name>brinzolamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and females 18 years of age or older,&#xD;
&#xD;
          -  diagnosed with primary open-angle glaucoma or ocular hypertension.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any form of glaucoma (such as secondary, congenital, juvenile or normal&#xD;
             tension glaucoma, angle closure glaucoma) in either eye other than primary open-angle&#xD;
             glaucoma,&#xD;
&#xD;
          -  ocular hypertension.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsey Mathew</last_name>
    <role>Study Director</role>
    <affiliation>Bausch Health Americas, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Various</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <results_first_submitted>May 14, 2021</results_first_submitted>
  <results_first_submitted_qc>May 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2021</results_first_posted>
  <disposition_first_submitted>May 20, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>May 20, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 24, 2019</disposition_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03896633/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Brinzolamide 1% Ophthalmic Suspension</title>
          <description>ophthalmic suspension&#xD;
brinzolamide 1% ophthalmic suspension: brinzolamide 1% ophthalmic suspension</description>
        </group>
        <group group_id="P2">
          <title>Azopt 1% Ophthalmic Suspension</title>
          <description>Ophthalmic suspension&#xD;
Azopt 1%: Azopt 1%, RLD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="321"/>
                <participants group_id="P2" count="316"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="312"/>
                <participants group_id="P2" count="306"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Brinzolamide 1% Ophthalmic Suspension</title>
          <description>ophthalmic suspension&#xD;
brinzolamide 1% ophthalmic suspension: brinzolamide 1% ophthalmic suspension</description>
        </group>
        <group group_id="B2">
          <title>Azopt 1% Ophthalmic Suspension</title>
          <description>Ophthalmic suspension&#xD;
Azopt 1%: Azopt 1%, RLD</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="321"/>
            <count group_id="B2" value="316"/>
            <count group_id="B3" value="637"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.1" lower_limit="20" upper_limit="91"/>
                    <measurement group_id="B2" value="63.8" lower_limit="20" upper_limit="90"/>
                    <measurement group_id="B3" value="64.4" lower_limit="20" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                    <measurement group_id="B2" value="190"/>
                    <measurement group_id="B3" value="389"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="443"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intraocular Pressure (IOP)</title>
        <time_frame>6 weeks</time_frame>
        <population>The Per Protocol Population was utilized for the primary outcome, included all randomized participants who met all inclusion/exclusion criteria, instilled 75% to 125% of the planned doses for the entire duration of the study, as verified by diaries, and who did not miss the scheduled applications for more than 3 consecutive days, and completed evaluations at Day 14 and Day 42 within the designated visit window (Â± 4 days) with no protocol deviations that would affect the treatment evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Brinzolamide 1% Ophthalmic Suspension</title>
            <description>ophthalmic suspension&#xD;
brinzolamide 1% ophthalmic suspension: brinzolamide 1% ophthalmic suspension</description>
          </group>
          <group group_id="O2">
            <title>Azopt 1% Ophthalmic Suspension</title>
            <description>Ophthalmic suspension&#xD;
Azopt 1%: Azopt 1%, RLD</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure (IOP)</title>
          <population>The Per Protocol Population was utilized for the primary outcome, included all randomized participants who met all inclusion/exclusion criteria, instilled 75% to 125% of the planned doses for the entire duration of the study, as verified by diaries, and who did not miss the scheduled applications for more than 3 consecutive days, and completed evaluations at Day 14 and Day 42 within the designated visit window (Â± 4 days) with no protocol deviations that would affect the treatment evaluation.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="292"/>
                <count group_id="O2" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.07" spread="3.269"/>
                    <measurement group_id="O2" value="19.89" spread="3.183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Intraocular Pressure (IOP)</title>
        <description>Change in intraocular pressure (IOP) from baseline (Eligibility Visit 2) and after treatment.</description>
        <time_frame>6 weeks</time_frame>
        <population>The Per Protocol Population was utilized for this outcome; included all randomized participants who met all inclusion/exclusion criteria, instilled 75% to 125% of the planned doses for the entire duration of the study, as verified by diaries, and who did not miss the scheduled applications for more than 3 consecutive days, and completed evaluations at Day 14 and Day 42 within the designated visit window (Â± 4 days) with no protocol deviations that would affect the treatment evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Brinzolamide 1% Ophthalmic Suspension</title>
            <description>ophthalmic suspension&#xD;
brinzolamide 1% ophthalmic suspension: brinzolamide 1% ophthalmic suspension</description>
          </group>
          <group group_id="O2">
            <title>Azopt 1% Ophthalmic Suspension</title>
            <description>Ophthalmic suspension&#xD;
Azopt 1%: Azopt 1%, RLD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Intraocular Pressure (IOP)</title>
          <description>Change in intraocular pressure (IOP) from baseline (Eligibility Visit 2) and after treatment.</description>
          <population>The Per Protocol Population was utilized for this outcome; included all randomized participants who met all inclusion/exclusion criteria, instilled 75% to 125% of the planned doses for the entire duration of the study, as verified by diaries, and who did not miss the scheduled applications for more than 3 consecutive days, and completed evaluations at Day 14 and Day 42 within the designated visit window (Â± 4 days) with no protocol deviations that would affect the treatment evaluation.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="292"/>
                <count group_id="O2" value="296"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.85" spread="2.792"/>
                    <measurement group_id="O2" value="-4.70" spread="2.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <desc>One Brinzolamide participant did not receive treatment and is not included in the participant counts for safety. Two Brinzolamide participants received at least one dose of Azopt in error, and therefore the Azopt group has 2 additional participants for safety.</desc>
      <group_list>
        <group group_id="E1">
          <title>Brinzolamide 1% Ophthalmic Suspension</title>
          <description>ophthalmic suspension&#xD;
brinzolamide 1% ophthalmic suspension: brinzolamide 1% ophthalmic suspension</description>
        </group>
        <group group_id="E2">
          <title>Azopt 1% Ophthalmic Suspension</title>
          <description>Ophthalmic suspension&#xD;
Azopt 1%: Azopt 1%, RLD</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="320"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="320"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="320"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Contact sponsor directly for details.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel Donatello</name_or_title>
      <organization>Bausch &amp; Lomb</organization>
      <phone>5853385306</phone>
      <email>Daniel.Donatello@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

